← back to search

Nicholas A. Meanwell

PA Consulting Group · GB
Area of research
Infectious Diseases · Materials Chemistry
Research interest
Research interests include HIV/AIDS drug development and treatment, Hepatitis C virus research, HIV Research and Treatment, and Crystallization and Solubility Studies.
h-index
63
citations
24,996
works
469
NIH funding
primary concept
email

Recent publications

Structural Aspects of Proline Methanologues in Drug Design, Optimization, and Development.
2026cited by 0position: contributordoi
A Data-Driven Perspective on Bioisostere Evaluation: Mapping the Benzene Bioisostere Landscape with BioSTAR.
2025cited by 7position: contributordoi
Carbon atom σ-hole tetrel bonding – a non-bonded interaction with potential application in drug design
Medicinal Chemistry Research 2025cited by 4position: contributordoi
Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-986408.
2025cited by 1position: contributordoi
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Signal Transduction and Targeted Therapy 2024cited by 157position: middledoi
Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates.
2024cited by 46position: contributordoi
Invention of VH-937, a Potent HIV-1 Maturation Inhibitor with the Potential for Infrequent Oral Dosing in Humans.
2024cited by 4position: contributordoi
Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937.
2024cited by 1position: contributordoi
Applications of Bioisosteres in the Design of Biologically Active Compounds.
2023cited by 91position: contributordoi
The pyridazine heterocycle in molecular recognition and drug discovery.
2023cited by 26position: contributordoi
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity.
2023cited by 19position: contributordoi
Potent Long-Acting Inhibitors Targeting the HIV-1 Capsid Based on a Versatile Quinazolin-4-one Scaffold.
2023cited by 18position: contributordoi
Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization.
2023cited by 14position: contributordoi
Anagrelide: A Clinically Effective cAMP Phosphodiesterase 3A Inhibitor with Molecular Glue Properties.
2023cited by 6position: contributordoi
Sub-stoichiometric Modulation of Viral Targets-Potent Antiviral Agents That Exploit Target Vulnerability.
2023cited by 3position: contributordoi
Some Observations and Guidance on Perspectives in the <i>Journal of Medicinal Chemistry</i>.
2023cited by 1position: contributordoi
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 1.
2022cited by 32position: contributordoi
Metallaphotoredox Decarboxylative Arylation of Natural Amino Acids via an Elusive Mechanistic Pathway
ACS Catalysis 2022cited by 32position: contributordoi
Advances in the synthesis of three-dimensional molecular architectures by dearomatizing photocycloadditions
Tetrahedron 2022cited by 28position: contributordoi
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2.
2022cited by 24position: contributordoi
The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation.
2022cited by 13position: contributordoi
Photo-Initiated Nickel Catalysis (PiNiC): Unmasking Dimethylnickel with Light
ACS Catalysis 2022cited by 9position: contributordoi
Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs.
2022cited by 8position: contributordoi
Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor.
2022cited by 7position: contributordoi
Electrophilic Hydrazination of Cyclopropanols Using Azodicarboxylates via Copper(II) Catalysis: An Umpolung Strategy to Access β-Hydrazino Ketone Motifs.
2022cited by 5position: contributordoi
Improving Drug Delivery While Tailoring Prodrug Activation to Modulate <i>C</i><sub>max</sub> and <i>C</i><sub>min</sub> by Optimization of (Carbonyl)oxyalkyl Linker-Based Prodrugs of Atazanavir.
2022cited by 2position: contributordoi
Synthetic Access to α-Oxoketene Aminals by the Nucleophilic Addition of Enol Silane-Derived Palladium(II) Enolates to Carbodiimides.
2022cited by 2position: contributordoi
Synthesis, Structure-Activity Relationships, and <i>In Vivo</i> Evaluation of Novel C-17 Amine Derivatives Based on GSK3640254 as HIV-1 Maturation Inhibitors with Broad Spectrum Activity.
2022cited by 1position: contributordoi
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design.
2021cited by 341position: contributordoi
Photocatalytic Dearomative Intermolecular [2 + 2] Cycloaddition of Heterocycles for Building Molecular Complexity.
2021cited by 37position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 53 papers (2019–2026)Murugaiah A. M. Subbaiah · American Chemical Society5 papers (2021–2024)Martins S. Oderinde · Bristol-Myers Squibb (Germany)5 papers (2020–2022)Gunda I. Georg · University of Minnesota5 papers (2020–2020)T. G. Murali Dhar · Scripps Research Institute5 papers (2020–2025)Alicia Regueiro-Ren · Bristol Myers Squibb5 papers (2019–2024)Kevin Peese · American Chemical Society4 papers (2019–2023)Richard A. Hartz · American Chemical Society4 papers (2022–2024)James Kempson · Bristol-Myers Squibb (Germany)4 papers (2020–2022)Antonio Ramirez · Bristol-Myers Squibb (United States)4 papers (2020–2022)Wendy Young · County of Sonoma Department of Health Services3 papers (2020–2021)B. Narasimhulu Naidu · 3 papers (2022–2023)Anuradha Gupta · American Chemical Society3 papers (2020–2022)Craig W. Lindsley · Vanderbilt University2 papers (2021–2023)Shaomeng Wang · Rogers (United States)2 papers (2020–2020)Hong Liu · Shenyang Pharmaceutical University2 papers (2020–2021)Barbara Zhizhen Zheng · Bristol-Myers Squibb (United States)2 papers (2020–2022)Xiaoping Hou · American Chemical Society2 papers (2022–2024)Li Xu · Cornell University2 papers (2022–2024)Andivelu Ilangovan · Bharathiar University2 papers (2022–2022)